Pulmonx (NASDAQ:LUNG) Now Covered by Analysts at D. Boral Capital

Analysts at D. Boral Capital assumed coverage on shares of Pulmonx (NASDAQ:LUNG) in a research note issued on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $17.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 127.27% from the company’s previous close.

Other analysts have also issued reports about the stock. Citigroup reiterated a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Wells Fargo & Company dropped their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.36.

Pulmonx Trading Up 0.5 %

Shares of LUNG stock opened at $7.48 on Monday. Pulmonx has a 1-year low of $5.46 and a 1-year high of $10.01. The firm has a market cap of $297.67 million, a PE ratio of -5.19 and a beta of 0.50. The company has a 50-day moving average of $6.96 and a two-hundred day moving average of $6.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, analysts predict that Pulmonx will post -1.55 EPS for the current year.

Insider Buying and Selling

In other news, Director Glendon E. French III sold 55,453 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the transaction, the director now owns 1,011,974 shares in the company, valued at approximately $8,379,144.72. This represents a 5.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the sale, the chief executive officer now directly owns 194,342 shares in the company, valued at $1,387,601.88. This trade represents a 12.47 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 127,986 shares of company stock worth $986,673. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Pulmonx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. State Street Corp boosted its holdings in shares of Pulmonx by 2.6% in the 3rd quarter. State Street Corp now owns 747,028 shares of the company’s stock valued at $6,193,000 after buying an additional 18,592 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in Pulmonx in the third quarter valued at $1,711,000. Geode Capital Management LLC grew its holdings in shares of Pulmonx by 1.3% during the third quarter. Geode Capital Management LLC now owns 892,786 shares of the company’s stock worth $7,403,000 after purchasing an additional 11,151 shares during the last quarter. Polar Asset Management Partners Inc. acquired a new stake in shares of Pulmonx during the third quarter worth about $893,000. Finally, Millrace Asset Group Inc. purchased a new stake in shares of Pulmonx in the 3rd quarter valued at about $1,390,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.